Topic: inflammatory bowel disease
Aurobindo and Glenmark are cited by the FDA. Takeda inks IBD discovery pact with Prometheus. Ascletis recruits Novartis veteran as CSO.
Eli Lilly is firing up its first innovation challenge for digital health, seeking technology solutions for inflammatory bowel disease.
In light of increased antitrust scrutiny over pharma M&A, AbbVie will also cut a few products to win U.S. clearance for its Allergan buyout.
Think the success of several megablockbusters such as AbbVie’s Humira means the anti-inflammation market is fully saturated? Think again.
The inflatable stolen colon is back in triplicate thanks to Salix Pharmaceutical employees.
The UCB-sponsored fledgling initiative to create a clinical care pathway for women with IBD who are considering pregnancy gets its first-ever awareness campaign.
The EU approval is conditional on selling off a Shire experimental IBD drug, which Takeda said could attract "a number of potential buyers."
Amid reports that it will sell Shire's Xiidra and Natpara, Takeda said it may sell SHP647, a phase 3 bowel drug that would overlap its own Entyvio.
UCB is sponsoring an effort to create a clinical care standard for women with inflammatory bowel disease (IBD) before, during and after pregnancy.
Drug materials are targets of U.S.-China trade war, analysts see more hope in the Takeda-Shire deal, China puts forward policies that favors generics over brands.